LLY Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
24.4B
+6.2%
23.0B
+16.0%
19.8B
+2.6%
19.3B
+9.6%
17.6B
Cost of Revenue
3.9B
+20.3%
3.3B
-8.6%
3.6B
+6.1%
3.4B
+12.1%
3.0B
Gross Profit
20.5B
+3.8%
19.7B
+21.5%
16.2B
+1.9%
15.9B
+9.1%
14.6B
Operating Expenses
11.9B
+10.5%
10.7B
+46.8%
7.3B
-3.2%
7.5B
+4.4%
7.2B
R&D
4.2B
+11.2%
3.8B
+8.8%
3.5B
-7.7%
3.8B
+9.7%
3.5B
SG&A
3.1B
-8.9%
3.4B
+16.9%
2.9B
-6.3%
3.1B
+14.2%
2.7B
Operating Income
8.6B
-4.1%
9.0B
+0.7%
8.9B
+6.5%
8.4B
+13.7%
7.4B
EBITDA
13.6B
+5.0%
13.0B
+26.3%
10.3B
+7.5%
9.6B
+8.1%
8.9B
Net Income
6.5B
-9.1%
7.1B
-4.1%
7.4B
+11.4%
6.6B
+18.9%
5.6B
EPS (Basic)
$7.23
-9.1%
$7.95
-3.9%
$8.27
+11.6%
$7.41
+19.1%
$6.22
EPS (Diluted)
$7.22
-9.1%
$7.94
-3.9%
$8.26
+11.8%
$7.39
+19.0%
$6.21
Shares (Diluted)
893.4M
-0.0%
893.7M
-0.2%
895.9M
-0.2%
898.0M
-0.1%
898.8M
Eli Lilly & (LLY) — Financials